Fusion Antibodies has announced a collaboration agreement regarding OptiMAL®, a technology platform for the optimization of monoclonal antibodies. The details of the collaboration agreement can be found in the provided link. The company has not provided any specific information about the collaboration or its partners in the announcement.

For any inquiries about Fusion Antibodies, the company suggests contacting Walbrook PR through phone or email. The announcement also includes a link for subscribers to remove their names from the Fusion Antibodies News Alert Service.

Please note that the provided news does not contain any specific information about the company's operations, financials, or other significant developments.